Sirnaomics Ltd
02257
Company Profile
Business description
Sirnaomics Ltd is a therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of drugs for indications with medical needs and large market opportunities. The Group's operations and non-current assets are located at the United States of America and the mainland of the People's Republic of China. All of the company's revenue is derived from the mainland of the People's Republic of China (the PRC). The pipeline includes: STP705, STP707, STP355, STP369, STP705, STP122G, STP125G, and STP144G.
Contact
No.218 Xinghu Street
Unit 415, A4 Building
Suzhou Industrial Park
Suzhou
CHNT: +86 51262956283
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
37
Stocks News & Analysis
stocks
Cheap ASX share may have more room to run
Shares are cheap despite rebounding share price, yet risks remain.
stocks
ASX listed media giant drives strong earnings growth
Digital growth drives earnings beat for media share.
stocks
ASX real estate platform outperforms yet questions remain
Valuation remains a key concern despite strong August reporting.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,421.80 | 15.60 | -0.17% |
| CAC 40 | 8,714.93 | 15.22 | 0.17% |
| DAX 40 | 26,319.45 | 179.32 | 0.69% |
| Dow JONES (US) | 54,036.93 | 151.83 | 0.28% |
| FTSE 100 | 10,901.09 | 33.20 | 0.31% |
| HKSE | 25,866.51 | 198.48 | 0.77% |
| NASDAQ | 26,690.62 | 342.26 | 1.30% |
| Nikkei 225 | 66,890.30 | 1,283.59 | 1.96% |
| NZX 50 Index | 13,888.24 | 64.11 | 0.46% |
| S&P 500 | 7,757.64 | 47.68 | 0.62% |
| S&P/ASX 200 | 9,231.40 | 18.20 | -0.20% |
| SSE Composite Index | 3,948.72 | 8.68 | 0.22% |